Arbutus Biopharma’s latest quarterly filings reveal significant strategic shifts, including the settlement of patent disputes with Moderna yielding a $950 million noncontingent payment and continued litigation progress against Pfizer/BioNTech. The company is focusing its clinical-stage assets on chronic hepatitis B treatments, notably imdusiran and AB-101, while maintaining strong liquidity with zero debt. The proprietary lipid nanoparticle (LNP) technology remains central to Arbutus’s competitive moat, underpinning its RNAi platform and license revenue streams. Key near-term developments include clinical trial advancements and litigation milestones that will shape the company's growth trajectory.